Head-To-Head Review: Citius Pharmaceuticals (NASDAQ:CTXR) and Klotho Neurosciences (NASDAQ:KLTO)

Klotho Neurosciences (NASDAQ:KLTO) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Profitability

This table compares Klotho Neurosciences and Citius Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Klotho Neurosciences	N/A	-201.60%	-171.30%
Citius Pharmaceuticals	N/A	-49.34%	-28.64%

Risk and Volatility

Klotho Neurosciences has a beta of 9.08, indicating that its share price is 808% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.

Insider and Institutional Ownership

20.1% of Klotho Neurosciences shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 9.9% of Klotho Neurosciences shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Klotho Neurosciences and Citius Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Klotho Neurosciences	1	0	0	0	1.00
Citius Pharmaceuticals	1	2	1	0	2.00

Citius Pharmaceuticals has a consensus target price of $6.00, suggesting a potential upside of 566.67%. Given Citius Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Klotho Neurosciences.

Valuation & Earnings

This table compares Klotho Neurosciences and Citius Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Klotho Neurosciences	N/A	N/A	-$6.15 million	($0.32)	-1.64
Citius Pharmaceuticals	N/A	N/A	-$37.43 million	($2.45)	-0.37

Klotho Neurosciences is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Citius Pharmaceuticals beats Klotho Neurosciences on 6 of the 11 factors compared between the two stocks.

About Klotho Neurosciences

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.